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clonal antibodies generated by recombinant PfCDPK-5 protein or
DNA vaccine shows signiﬁcant growth inhibition activity in in vitro
assays. Anti-rPfCDPK-5 antibody levels in the entire cohort shows
a positive correlation to morbidity and mortality of children.
PfCDPK-5 phosphorylate PfSEA-1
Conclusion: In the present study, we validate a rationally iden-
tiﬁed vaccine candidate, P. falciparum calcium-dependent protein
kinase 5(PfCDPK-5) using integrated translational approaches that
harness high-throughput molecular techniques and in vitro func-
tional assays.
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Background: Vaccine safety is one of the critical parameters
for quality assurance in immunization program in all countries
including developing country like India as it adds new vaccines to
its existing immunization program. Occurrence of adverse events
following immunization (AEFI) and spread of unchecked rumors
can hamper community conﬁdence in vaccines adversely affect-
ing coverage. Cluster AEFI (2 or more reports occurring together)
get heightened attention from media, government and community
and can affect performance of immunization program. In commit-
ment to improve vaccine safety, this paper summarizes a report
of a cluster investigation for AEFIs (90 reports) following Japanese
Encephalitis (JE) vaccine given in a mass campaign in one district
(Morigoan of Assam), India in June, 2014.
Methods & Materials: In response to received reports of AEFI
cluster over 10 day’s period in June 2014, National AEFI surveil-
lance team had investigated the reason for the events in the ﬁeld
by interviewing community and reviewing hospital records. Data
of the individual cases was entered in anonymized line list and
analyzed by using SPSS vs. 16.
Results: In Morigoan, 200574 doses of JE vaccine was adminis-
tered in 1- 15 years age groupduring 15days period in 2014 inmass
campaignandamong these89of the caseshave reported symptoms
of dizziness, tingling and numbness and abnormal movement of
limbs.More than two- thirdof theaffected individualswere females
having median age of 9 years. Cases recovered without any resid-
ual sequel after receiving conservative treatment, reassurance and
counselling in hospital.
Conclusion: There is a need of multi-pronged, effective infor-
mation, education and communication intervention to handle
unwanted rumors to ensure vaccine conﬁdence during mass cam-
paign by involving multiple stake holders.
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Background: Despite the introduction of inactivated Japanese
encephalitis (JE) vaccine since 1990, JE remains an important cause
of viral encephalitis in Thailand. Little is known about JE serosta-
tus among Thais who were born before the 2001, the year that this
vaccine has been included in the expanded immunization program.
Therefore, the objective of this study was to determine the propor-
tion of healthcareworkers (HCWs) aged 21-60 yearswith adequate
neutralizing antibody against JE virus.
Methods & Materials: We conducted a seroprevalence survey
among HCWs during the routine annual check-up for HCWs at
Queen Sirikit National Institute of ChildHealth (Children’sHospital,
Bangkok, Thailand)during theperiodbetween July-October2015.A
purposive samplingwas done to enroll a relatively equal number of
4 different age ranges i.e., 21-30, 31-40, 41-50, and 51-60 years per
each group. JE serostatus was determined using 50% Plaque Reduc-
tion Neutralization Test (PRNT). Immunity to JE were quantitated
and cross-tabulated against age, gender, past and present domicile,
history of JE vaccination, types of vaccine received (if any).
Results: A total of 400 HCWs among a total of 1,320 who
received annual check-up were enrolled. Only 1.5% of participants
reported having immunized with JE vaccine. 80.5% demonstrated
an adequate existing antibody against JE virus genotype 3 Beijing
strain (at least 10 reciprocal PRNT titer). The proportion of protec-
tive antibody (and corresponding geometric mean titer) of the 4
age groups were 77.0% (112.48), 82.4% (211.47), 80.6% (84.59), and
82.0%(126.97) among those aged 21-30, 31-40, 41-50, and 51-60,
respectively.Male genderwas the only parameter that signiﬁcantly
associatedwith the lack of protective JE antibodywith risk ratio and
95% conﬁdence interval of 1.69 (1.1, 2.7).
Conclusion: Since JE virus is unlikely to be transmitted in hospi-
tal settings, the result from this groupmight be reﬂective of those in
the general adult population in Bangkok. As a result, approximately
